Siemens teams up with NYU Medical Center
NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the
NYU Medical Center has entered into a strategic alliance with Siemens Medical Solutions. The cornerstone of the alliance is a seven-year agreement that makes Siemens the exclusive supplier of the center's radiology imaging. The commercial value of the agreement will exceed $110 million, according to the company. The agreement covers approximately 100 advanced imaging systems, including a high-resolution research 7T MR scanner. Also included will be CTs, PET scanners, mammography, digital x-ray, and ultrasound equipment, as well as PACS. Due to the size and scope of the agreement, NYU and Siemens expect it will take four years to install all of the equipment and systems.
Another key aspect of the alliance is the commitment from both partners to MR imaging research. NYU plans to construct a new MR research facility near its midtown campus in Manhattan to house some of the new equipment, including the new 7T system, which will require a special room reinforced by some 300 tons of steel. Siemens will also install two 3T scanners dedicated to imaging research, particularly of the human brain, liver, kidneys, and prostate.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
